Table 2. Results: Gait improvement (Part 2).
| SRN | Year (country) | Type | Sample (age)* | RP | Adverse events |
|---|---|---|---|---|---|
| 29 | 2016 (Belgium) | RC | 53 (4–18) | P | NI |
| 30 | 2016 (South Korea) | CT | 25 (3–15) | P | NI |
| 31 | 2016 (Australia) | PC | 10 (6–16) | NI | NI |
| 32 | 2016 (USA) | CT | 241 (2–17) | P | temporary muscle weakness |
| 33 | 2014 (Australia) | CT | 6 (8–9) | P | A |
| 34 | 2014 (Belgium) | CT | 31 (3–18) | P | NI |
| 35 | 2014 (China) | CT | 37 (3–15) | P | NI |
| 36 | 2014 (Turkey) | CT | 33 (2–8) | P | A |
| 37 | 2014 (Belgium) | CT | 19 (3–18) | P | NI |
| 38 | 2013 (Australia) | CT | 15 (5–12) | P | NI |
| 39 | 2012 (South Korea) | CT | 40 (2–14) | NI | NI |
| 40 | 2012 (South Korea) | CT | 17 (2–9) | P | A |
| 41 | 2022 (Czech Republic) | CT | 370 (2–17) | POT | seizure in patient with epilepsy, constipation and muscle weakness |
| 42 | 2022 (USA) | CT | 381 (2–17) | P | upper respiratory tract infections, followed by fever and cough |
| 43 | 2021 (USA) | CSR | 1508 (0–19) | P | NI |
| 44 | 2021 (Poland) | NSR | 945 (NI) | POT | respiratory tract infection, bronchitis, pharyngitis, asthma, muscle weakness, urinary incontinence, falls, seizures, temporary low-grade fever, and pain at the application site |
| 45 | 2019 (Turkey) | SR | 153 (11mo–15yrs) | P | pain, redness, and dysesthesia at the application site, and muscle weakness |
| 46 | 2018 (Canada) | Q | 15 (5–17) | NI | NI |
| 47 | 2016 (China) | CT | 4 (5–8) | POT | NI |
| 48 | 2014 (Poland) | CT | 41 (2–15) | P | A |
| 49 | 2014 (South Korea) | CT | 25 (2–6) | NI | NI |
| 50 | 2013 (Brazil) | CT | 14 (2–18) | P | A |
| 51 | 2013 (China) | CT | 244 (1–23) | P | NI |
*Years. SRN: study reference number; RP: rehabilitation program; RC: retrospective cohort; P: physiotherapy; NI: not informed; CT: clinical trial; PC: prospective cohort; A: absent; POT: physiotherapy and occupational therapy; CSR: Cochrane systematic review; NSR: non-systematic review; SR: systematic review; Q: qualitative.